Biomolecular predictors of urothelial cancer behavior and treatment outcomes.
Standard
Biomolecular predictors of urothelial cancer behavior and treatment outcomes. / Rink, Michael; Cha, Eugene K; Green, David; Hansen, Jens; Robinson, Brian D; Lotan, Yair; Sagalowsky, Arthur I; Chun, Felix; Karakiewicz, Pierre I; Fisch, Margit; Scherr, Douglas S; Shariat, Shahrokh F.
In: CURR UROL REP, Vol. 13, No. 2, 2, 2012, p. 122-135.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Biomolecular predictors of urothelial cancer behavior and treatment outcomes.
AU - Rink, Michael
AU - Cha, Eugene K
AU - Green, David
AU - Hansen, Jens
AU - Robinson, Brian D
AU - Lotan, Yair
AU - Sagalowsky, Arthur I
AU - Chun, Felix
AU - Karakiewicz, Pierre I
AU - Fisch, Margit
AU - Scherr, Douglas S
AU - Shariat, Shahrokh F
PY - 2012
Y1 - 2012
N2 - Urothelial carcinoma of the urinary bladder (UCB) is a highly heterogeneous malignancy that causes significant morbidity and mortality. Despite advances in surgical and medical treatment, there has been no change in mortality in UCB over the past decades. Standard pathological features (stage, grade, nodal status) provide only limited information regarding biological potential and clinical behavior. Molecular biomarkers may shed light on important mechanisms of pathogenesis, provide useful additional prognostic information, and serve as targets for therapy. This review summarizes recent advances and the most promising UCB tissue and blood biomarkers of the past few years. We discuss the predictive and prognostic value of biomarkers at different stages of UCB. There is no doubt that a panel of biomarkers will eventually improve our clinical decision-making with regard to treatment and follow-up.
AB - Urothelial carcinoma of the urinary bladder (UCB) is a highly heterogeneous malignancy that causes significant morbidity and mortality. Despite advances in surgical and medical treatment, there has been no change in mortality in UCB over the past decades. Standard pathological features (stage, grade, nodal status) provide only limited information regarding biological potential and clinical behavior. Molecular biomarkers may shed light on important mechanisms of pathogenesis, provide useful additional prognostic information, and serve as targets for therapy. This review summarizes recent advances and the most promising UCB tissue and blood biomarkers of the past few years. We discuss the predictive and prognostic value of biomarkers at different stages of UCB. There is no doubt that a panel of biomarkers will eventually improve our clinical decision-making with regard to treatment and follow-up.
KW - Humans
KW - Male
KW - Female
KW - Predictive Value of Tests
KW - Prognosis
KW - Risk Assessment
KW - Survival Analysis
KW - Combined Modality Therapy
KW - Disease-Free Survival
KW - Neoplasm Staging
KW - Tumor Markers, Biological/metabolism
KW - Urothelium/pathology
KW - Neoplasm Invasiveness/pathology
KW - Carcinoma, Transitional Cell/metabolism/mortality/pathology/therapy
KW - Cystectomy/methods
KW - Urinary Bladder Neoplasms/metabolism/mortality/pathology/therapy
KW - Humans
KW - Male
KW - Female
KW - Predictive Value of Tests
KW - Prognosis
KW - Risk Assessment
KW - Survival Analysis
KW - Combined Modality Therapy
KW - Disease-Free Survival
KW - Neoplasm Staging
KW - Tumor Markers, Biological/metabolism
KW - Urothelium/pathology
KW - Neoplasm Invasiveness/pathology
KW - Carcinoma, Transitional Cell/metabolism/mortality/pathology/therapy
KW - Cystectomy/methods
KW - Urinary Bladder Neoplasms/metabolism/mortality/pathology/therapy
M3 - SCORING: Journal article
VL - 13
SP - 122
EP - 135
JO - CURR UROL REP
JF - CURR UROL REP
SN - 1527-2737
IS - 2
M1 - 2
ER -
